Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > RE: RE: Clinical Trial
View:
Post by FredZarfloon on Jul 11, 2023 7:14pm

RE: RE: Clinical Trial

Actually if you click on the exclamation mark next to "PRIMARY COMPLETION (Estimated)" it says "The "estimated" primary completion date is the date that the researchers think will be the primary completion date for the study" so I'll go with that definition. .

Comment by Rumpl3StiltSkin on Jul 11, 2023 8:41pm
As an investor I'm more concerned about when TLT will have real money coming into the till, $$ leverage to go into negotiations with, etc. According to the last corporate presentation, that was discussed here last week, from mid May. There was a timeline that discussed premarket approval(AA I assume),  BTD etc. That Premarket approval timeline had a very large period from 3rd qtr of this ...more  
Comment by Yajne on Jul 11, 2023 9:58pm
"That Premarket approval timeline had a very large period from 3rd qtr of this year to the end of 2025." Rump, I interpreted that large period to be the timeline for 'operating' under the premarket approval, not that AA could be granted anytime within that timeline. I'm optimistically assuming that AA is projected to occur during 2023 and then they would operate under ...more  
Comment by Rumpl3StiltSkin on Jul 12, 2023 1:38pm
Hey Yaj, I'd love AA to happen this year.  :-)
Comment by Eoganacht on Jul 12, 2023 1:54pm
If we got AA we could start charging for treatments. But would we? In the interests of getting the trial completed as soon as possible, might not Theralase use our FDA early approval as a way of attracting patients? In one of his recent interviews Roger talked about the difficulty of attracting NMIBC patients with CIS away from the bigger, more high profile clinical trials. The fact that the FDA ...more  
Comment by BlueFranky on Jul 12, 2023 2:05pm
Like your thinking Eog..    What we miss on the swing, we would more than make up for on the merry-go-round by attracting eyes and ears on all fronts,  hastening the trial completion.. improving our numbers exponentially along the way.. ...with several jockeys increasingly focused on this "one and done" dark horse ;-)
Comment by Rumpl3StiltSkin on Jul 12, 2023 3:33pm
Well, that is a good point. We only have another ~40 or so to treat for the trial, maybe pay for those, or would insurance cover? But anyone else that wanted 1433 for NMIBC or something off label like melanoma, could pay or get thier insurance company to..?? IMO. I think they sigaled it would be expensive.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250